The State-Court End Run: How Bayer’s $7.25 Billion Roundup Deal Rewrites the Mass Tort Playbook

The Holy Grail of Global Peace

For mass tort defense counsel, the white whale has always been "global peace"—a single, binding resolution that definitively caps corporate liability. But ever since the Supreme Court’s landmark rulings in Amchem Products, Inc. v. Windsor, 521 U.S. 591 (1997), and Ortiz v. Fibreboard Corp., 527 U.S. 815 (1999), certifying a nationwide personal injury class action for settlement in federal court under Federal Rule of Civil Procedure 23 has been virtually impossible. The predominance of individualized medical histories, varying state laws, and distinct exposure levels consistently shatters the Rule 23(b)(3) framework.

So, what happens when a corporate defendant still desperately needs to resolve tens of thousands of claims but knows the federal front door is locked? You get creative. You bypass the federal judiciary entirely.

Bayer’s Missouri Gambit and the Federal Abdication

In one of the most structurally significant developments in recent civil litigation history, Bayer attempted to resolve tens of thousands of Roundup product-liability suits through a staggering $7.25 billion class-action settlement. But they didn't file this in a federal multidistrict litigation (MDL) court—they filed it in Missouri state court.

Objectors, predictably terrified by the prospect of a single state-court judge binding a nationwide class of personal injury plaintiffs, attempted to derail the maneuver in federal court. Their argument was rooted in fundamental federalism and due process: a state court simply lacks the constitutional mandate and jurisdictional muscle to implement a nationwide resolution of this magnitude without trampling on absent class members' rights.

But the federal judiciary just gave Bayer the ultimate green light. In June 2026, a federal district judge formally sent the proposed settlement back to Missouri state court, rejecting the objectors' bid to keep the dispute in the federal forum. Then, in September 2026, the Eighth Circuit hammered the final nail into the objectors' coffin, outright dismissing the appellate challenge to Bayer’s state-court resolution effort.

The CAFA Irony

To understand why this is a seismic shift for practicing litigators, you have to look at the Class Action Fairness Act of 2005 (CAFA), 28 U.S.C. § 1332(d). Congress enacted CAFA precisely to prevent this exact scenario. The legislative history of CAFA is essentially a screed against "magic jurisdiction" state courts rubber-stamping massive, nationwide settlements that compromise the claims of out-of-state plaintiffs. CAFA was explicitly designed to ensure that nationwide class actions involving more than 100 members and $5 million in controversy are easily removable to federal court, where the stringent gatekeeping of Rule 23 applies.

Yet, when presented with a $7.25 billion nationwide personal injury settlement, the federal courts washed their hands of it. Whether the Eighth Circuit's dismissal was an exercise of its discretion to deny an appeal of a remand order under 28 U.S.C. § 1453(c), or a broader refusal to enjoin the state proceedings under the Anti-Injunction Act, 28 U.S.C. § 2283, the practical result is identical. The state-court end run works.

"If federal courts refuse to scrutinize state-court mega-settlements via CAFA removal or injunctions, defense counsel are essentially invited to forum-shop for the most compliant state-court judge in the country to rubber-stamp a global deal."

Why Defendants Are Fleeing the Federal Forum

Bayer’s victory in the Eighth Circuit doesn't exist in a vacuum. It is a direct reaction to an increasingly hostile federal appellate environment for mass tort defendants. Just look at the other major civil litigation developments from September 2026 that are keeping defense counsel awake at night:

• The Tylenol/Autism Revival: Tylenol’s maker and retailers are currently begging a federal appeals court to revisit a devastating decision that revived more than 500 private lawsuits alleging a link between the painkiller and autism. Despite the December 2023 amendments tightening Federal Rule of Evidence 702 (Daubert), federal appellate courts are proving they will still occasionally lower the drawbridge, allowing controversial epidemiological claims to reach juries.
• The PFAS Occupational Expansion: Reuters reported in September that 3M and DuPont must face a massive, class-style lawsuit from Connecticut firefighters over "forever chemicals" (PFAS) in federal court. As PFAS litigation shifts from municipal water cleanup to direct occupational exposure and personal injury classes, the federal docket is becoming a minefield of uncapped liability.

When the federal MDL track looks like a one-way ticket to endless trial dockets and unpredictable Daubert reversals, defendants have every incentive to look elsewhere. The Missouri state court offered Bayer a centralized, streamlined mechanism to buy global peace.

The New Mass Tort Playbook

For plaintiff and defense counsel alike, the Eighth Circuit’s dismissal of the Roundup challenge is a massive flashing sign that the rules of engagement have changed.

For the defense bar: The state-court settlement class is officially back on the menu. If you can structure a global resolution that survives initial federal removal attempts—perhaps by carefully navigating CAFA's local controversy exceptions or relying on the reluctance of federal appellate courts to intervene in state-court settlements—you can bypass the ghost of Amchem entirely. Finding a pragmatic state court willing to exercise nationwide jurisdiction is now your primary settlement objective.

For plaintiffs